Mechanisms of Diuretic Resistance in Heart Failure, Aim 1

PHASE1RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

May 1, 2026

Study Completion Date

November 1, 2026

Conditions
Heart Failure
Interventions
DRUG

Bumetanide Injection

Participants in balance will present to the study site Day 0 and receive their first randomized dose of bumetanide (1.25mg, 2.5mg, 5mg, or 10mg) and undergo the bio-specimen collection protocol. They will return every 3 days, allowing 2 full days washout, to receive the other doses in random sequence.

Trial Locations (1)

06510

RECRUITING

Yale University, New Haven

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Yale University

OTHER